Journal Mobile Options
Table of Contents
Vol. 67, No. 1, 2013
Issue release date: December 2012
Neuropsychobiology 2013;67:33–40
(DOI:10.1159/000343501)

Metabolic and Glutathione Redox Markers Associated with Brain-Derived Neurotrophic Factor in Depressed African Men and Women: Evidence for Counterregulation?

Harvey B.H. · Hamer M. · Louw R. · van der Westhuizen F.H. · Malan L.
aUnit for Drug Research and Development, Division of Pharmacology, School for Pharmacy, bCentre for Human Metabonomics and cHypertension in Africa Research Team (HART), School for Physiology, Nutrition and Consumer Sciences, North-West University, Potchefstroom, South Africa; dDepartment of Epidemiology and Public Health, University College of London, London, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Major depression is associated with evidence for metabolic and redox imbalance and also with reports of lower serum levels of brain-derived neurotrophic factor (BDNF). However, the relationship between these factors has not been well studied. Methods: We studied the contribution of physiological risk factors to cardiometabolic health in 200 adult male and female black Africans, aged between 36 and 52 years, presenting with (n = 89) and without (n = 111) symptoms of depression. Specifically the association between serum BDNF and markers of basal metabolic and redox status in depressed versus nondepressed individuals were analyzed. Results: BDNF and markers of redox and metabolic status were not associated with the symptoms of depression. Waist circumference, a metabolic risk factor, was positively associated with BDNF and accounts for 49% of the variance in BDNF in depressed men. Reduced and oxidized glutathione were positively and negatively correlated with BDNF in depressed women, respectively, with glutathione redox status accounting for 36–42% of the variance in BDNF. Conclusion: Selected metabolic and redox factors explained gender-specific variances in serum BDNF levels in depressed African men and women. Our findings suggest that changes in redox and metabolic status may represent counterregulation by BDNF or alternatively that BDNF may mediate undesirable redox and metabolic changes that are associated with the development of a mood disorder.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593–602.
  2. Kessler RC, Chiu WT, Demler O, Walters EE: Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005;62:617–627.
  3. Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, et al: Gender differences in depression: findings from the STAR*D study. J Affect Disord 2005;87:141–150.
  4. Möller-Leimkühler AM: Higher comorbidity of depression and cardiovascular disease in women: a biopsychosocial perspective. World J Biol Psychiatry 2010;11:922–933.
  5. Lazarus RS: Coping theory and research: past, present, and future. Psychosom Med 1993;55:234–247.
  6. Koolhaas JM, De Boer SF: Coping styles and aggression: a biobehavioral approach; in Vingerhoets A, Nylicek I, Denollet J (eds): Emotion Regulation: Conceptual and Clinical Issues. Berlin, Springer, 2008, pp 12–20.
  7. Malan L, Malan NT, Wissing MP, Seedat YK: Coping with urbanization: a cardiometabolic risk? The THUSA study. Biol Psychol 2008;79:323–328.
  8. Appels A: Mental precursors of myocardial infarction. Br J Psychiatry 1990;56:465–471.

    External Resources

  9. Korner PI: Essential Hypertension and Its Causes: Neural and Non-Neural Mechanisms. New York, Oxford University Press, 2007, pp 347–358.
  10. Hamer M, Malan L: Psychophysiological risk markers of cardiovascular disease. Neurosci Biobehav Rev 2010;35:76–83.
  11. McEwen BS: Stress, adaptation, and disease. Allostasis and allostatic load. Ann NY Acad Sci 1998;840:33–44.
  12. McEwen BS: Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87:873–904.
  13. Okamura F, Tashiro A, Utumi A, Imai T, Suchi T, Tamura D, et al: Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000;49:1255–1260.
  14. Dager SR, Friedman SD, Parow A, et al: Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 2004;61:450–458.
  15. Regenold WT, Phatak P, Kling MA, Hauser P: Post-mortem evidence from human brain tissue of disturbed glucose metabolism in mood and psychotic disorders. Mol Psychiatry 2004;9:731–733.
  16. Regenold WT, Hisley KC, Obuchowski A, Lefkowitz DM, Marano C, Hauser P: Relationship of white matter hyperintensities to cerebrospinal fluid glucose polyol pathway metabolites – a pilot study in treatment-resistant affective disorder patients. J Affect Disord 2005;85:341–350.
  17. Kruse J, Petrak F, Herpertz S, Albus C, Lange K, Kulzer B: Diabetes and depression – a life-endangering interaction (in German). Z Psychosom Med Psychother 2006;52:289–309.
  18. Hamer M, Batty GD, Kivimaki M: Haemoglobin A1c, fasting glucose and future risk of elevated depressive symptoms over 2 years of follow-up in the English Longitudinal Study of Ageing. Psychol Med 2011;41:1889–1896.
  19. Harvey BH: Is major depressive disorder a metabolic encephalopathy? Hum Psychopharmacol 2008;23:371–384.
  20. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al: The inflammatory and neurodegenerative hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009;24:27–53.
  21. Dantzer R, O’Connor JC, Lawson MA, Kelley KW: Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011;36:426–436.
  22. Greco CM, Kao AH, Sattar A, Danchenko N, Maksimowicz-McKinnon KM, Edmundowicz D, et al: Association between depression and coronary artery calcification in women with systemic lupus erythematosus. Rheumatology 2009;48:576–581.
  23. Joynt KE, Whellan DJ, O’Connor CM: Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry 2003;54:248–261.
  24. Shively CA, Musselman DL, Willard SL: Stress, depression, and coronary artery disease: modeling comorbidity in female primates. Neurosci Biobehav Rev 2009;33:133–144.
  25. Gardner A, Boles RG: Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:730–743.
  26. Ng F, Berk M, Dean O, Bush AI: Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008;11:851–876.
  27. Bains JS, Shaw CA: Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev 1997;25:335–358.
  28. Johnson F, Giulivi C: Superoxide dismutases and their impact upon human health. Mol Aspects Med 2005;26:340–352.
  29. Garcia-Cazorla A, Duarte S, Serrano M, Nascimento A, Ormazabal A, Carrilho I, et al: Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 2008;8:273–278.
  30. Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64:527–532.
  31. Dwivedi Y: Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat 2009;5:433–449.
  32. Martinez JM, Garakani A, Yehuda R, Gorman JM: Proinflammatory and ‘resiliency’ proteins in the CSF of patients with major depression. Depress Anxiety 2012;29:32–38.
  33. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ: Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998;37:1553–1567.
  34. Karege F, Schwald M, Cisse M: Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002;328:261–264.
  35. Schmidt HD, Duman RS: Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010;35:2378–2391.
  36. Obrist PA: Cardiovascular Psychophysiology: A Perspective. London, Plenum, 1981, pp 18–23.
  37. Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–613.
  38. Monahan PO, Shacham E, Reece M, Kroenke K, Ong’or WO, Omollo O, et al: Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults living with HIV/AIDS in western Kenya. J Gen Intern Med 2009;24:189–197.
  39. Marfell-Jones M, Olds T, Stewart A, Carter JE: International Standards for Anthropometric Assessment. Potchefstroom, ISAK, 2006, p 137.
  40. Klippel NJ, Heil DP: Validation of energy expenditure prediction algorithms in adults using the Actical electronic activity monitor. Med Sci Sports Exerc 2003;35:S284.
  41. Jarvis MJ, Feyerabend C, Bryant A, Hedges B, Primatesta P: Passive smoking in the home: plasma cotinine concentrations in non-smokers with smoking partners. Tob Control 2001;10:368–374.
  42. Sharpe PC: Biochemical detection and monitoring of alcohol abuse and abstinence. Ann Clin Biochem 2001;38:652–664.
  43. Tietze F: Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Ann Biochem 1969;27:502–522.
  44. Grundy MS, Brewer H, Cleeman JI, Daniels SR, Donaato KA, Eckel RH, et al: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation 2005;112:2735–2752.
  45. Prinsloo J, Malan L, de Ridder JH, Potgieter JC, Steyn HS: Determining the waist circumference cut off which best predicts the metabolic syndrome components in urban Africans: the SABPA study. Exp Clin Endocrinol Diabetes 2011;119:599–603.
  46. Maes M, Ruckoanich P, Chang YS, Mahanonda N, Berk M: Multiple aberrations in shared inflammatory and oxidative and nitrosative stress pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:769–783.
  47. Griffith OW: Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 1999;27:922–935.
  48. Bouligand J, Deroussent A, Paci A, Morizet J, Vassal G: Liquid chromatography – tandem mass spectrometry assay of reduced and oxidized glutathione and main precursors in mice liver. J Chromatogr B 2006;832:67–74.
  49. Wong ML, Dong C, Andreev V, Arcos-Burgos M, Licinio J: Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environmental factors. Mol Psychiatry 2012;17:624–633.
  50. Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J, Elzinga BM, Voshaar RC: Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011;36:228–239.
  51. Grant MM, Barber VS, Griffiths HR: The presence of ascorbate induces expression of brain-derived neurotrophic factor in SH-SY5Y neuroblastoma cells after peroxide insult, which is associated with increased survival. Proteomics 2005;5:534–540.
  52. He T, Katusic ZS: Brain-derived neurotrophic factor increases expression of MnSOD in human circulating angiogenic cells. Microvasc Res 2012;83:366–371
  53. Duan W, Guo Z, Jiang H, Ware M, Mattson MP: Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 2003;144:2446–2453.
  54. Numakawa T, Matsumoto T, Numakawa Y, Richards M, Yamawaki S, Kunugi H: Protective action of neurotrophic factors and estrogen against oxidative stress-mediated neurodegeneration. J Toxicol 2011;2011:405194.

    External Resources

  55. Castrén E, Võikar V, Rantamäki T: Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007;7:18–21.
  56. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O’Leary OF, et al: The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008;320:385–388.
  57. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al: Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011;10:123–130.
  58. Castrén E: Is mood chemistry? Nat Rev Neurosci 2005;6:241–246.
  59. Meyer M, Matsuoka I, Wetmore C, Olson L, Thoenen H: Enhanced synthesis of brain-derived neurotrophic factor in the lesioned peripheral nerve: different mechanisms are responsible for the regulation of BDNF and NGF mRNA. J Cell Biol 1992;119:45–54.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50